Navigation Links
Creabilis Appoints George F. Horner III as its Chairman
Date:9/15/2010

Creabilis Appoints George F. Horner III as its Chairman -- LUXEMBOURG, September 15, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Banking & Financial Services, Biotechnology, Pharmaceuticals, Personnel Announcements Click to view news release full screen  

Creabilis Appoints George F. Horner III as its Chairman

 

LUXEMBOURG, September 15, 2010 /PRNewswire/ -- Creabilis SA, a clinical stage European biotechnology company addressing significant unmet medical needs in dermatological diseases, today announced the appointment of George F. Horner III as its Chairman. Mr Horner brings to Creabilis an unrivalled track record in building successful biotech businesses that have generated significant value for their shareholders.

Mr Horner has over 40 years industry experience gained with both biotech and big pharma companies. He was most recently the CEO of Prestwick Pharmaceuticals, a private CNS company that was sold to Biovail Corporation and Ovation Pharmaceuticals in late 2008. Prior to joining Prestwick, Mr Horner was the CEO of Vicuron, a publicly listed anti-infectives company that was sold to Pfizer for $1.9 billion in 2005. Mr Horner also worked for Ligand Pharmaceuticals following a successful career at Abbott Laboratories where his final position was as President of the company's business in Canada. Mr Horner has also acted as an adviser to a number of specialist life science investors in recent years.

Commenting on his new role, George F. Horner III said: "I am excited to be joining Creabilis given its potential to deliver the genuine innovation that is needed to transform the dermatology market. I have been attracted to this opportunity by the Company's rich pipeline of clinical and pre-clinical drug candidates focussed on dermatological indications, its deep understanding of the science behind a number of serious skin disorders, as well as its unique technology platform with broad utility. I am sure that from this strong base we will be able to generate significant value for Creabilis shareholders."

Graziano Seghezzi, Partner at Sofinnova, said: "We are delighted to have someone with George's track record in building successful high-value biotech businesses as Chairman of Creabilis. I am sure his strategic and operational experience will be vital as we look to progress the Company's exciting pipeline, build the management team and develop our LSE (Low Systemic Exposure) technology, so that Creabilis can generate new prescription medicines that will make a significant improvement to the treatment of skin diseases."

About Creabilis SA

Creabilis is a clinical stage European biotechnology company creating highly innovative new drugs to tackle unmet medical needs in serious dermatological diseases. Bringing together world class drug development capabilities and a rich scientific heritage, Creabilis is uniquely positioned to transform the treatment of skin diseases.

Creabilis' lead product is CT327, a novel topically applied TrkA kinase inhibitor developed using the Company's LSE (Low Systemic Exposure) technology. LSE technology creates new chemical entities with ideal characteristics for topical application (high local concentrations combined with low systemic exposure). CT327 is currently in Phase II clinical trials in psoriasis and atopic dermatitis. The Creabilis portfolio also includes CT637, a new approach to the treatment of significant inflammatory conditions such as rheumatoid arthritis as well as severe psoriasis. Earlier stage projects include a number of highly promising candidates for dermatological and wider indications.

Creabilis is backed by some of Europe's most highly respected life sciences investors including Sofinnova Partners and Neomed.

For more information, please visit: http://www.creabilis-sa.com For further information please contact: Creabilis SA E-mail: info@creabilis-sa.com Creabilis SA 15 Rue Edward Steichen L-2540 LUXEMBOURG Citigate Dewe Rogerson Chris Gardner or Nina Enegren Tel: +44(0)20-7282-1050 E-mail: nina.enegren@citigatedr.co.uk
'/>"/>

SOURCE Creabilis SA
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Elsevier Appoints Suzanne BeDell as Managing Director, Science and Technology (S&T) Books
2. ZS Associates Appoints Pharmaceutical Industry Veteran to Serve the Firms Growing Client Base in Germany
3. BioStorage Technologies Appoints New Global Director of Supply Chain
4. Mindray Appoints Mr. Minghe Cheng as Chief Strategic Officer
5. Pevion Biotech Appoints New CEO and Secures CHF 10 Million Financing
6. Hill-Rom Appoints Scott Jeffers as Senior Vice President, Global Supply Chain
7. PharmaVentures Appoints Paul Phull as Senior Director
8. Kendle Appoints Mark J. Roseman, D.Sc., Senior Vice President and Chief Marketing Officer
9. Jennerex Appoints Lara Longpre to Chief Operating Officer
10. Regenicin Appoints Amgen Co-founder Dr. Joseph Rubinfeld to Board of Directors
11. Fluidnet Corporation Appoints Benjamin E. Bulkley President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Consumers have ... and regulators/payers have placed more emphasis on patient ... patient support programs in the pharmaceutical industry have ... medications. Consequently, pharmaceutical companies are focusing on becoming ... are providing products and services that improve health. ...
(Date:6/24/2016)... , June 24, 2016 ... the "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" ... In-Mold Electronics, Smart Skin, Structural ... Structural electronics involves electronic and/or ... protective structures, replacing dumb structures such as vehicle ...
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... legally blind and certified personal trainer is helping to develop a weight loss fitness plan ... fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
Breaking Medicine News(10 mins):